Ascelia Pharma AB AI Stock Analysis
Ascelia Pharma AB (7ZA) AI Stock Analysis
Ascelia Pharma AB
(Frankfurt:7ZA)
No summary available
Ascelia Pharma AB (7ZA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 6.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 13.00K
- Price to Earnings (P/E)
- -1.3
- Beta (1Y)
- 55.11
- Revenue Growth
- ―
- EPS Growth
- 49.02%
- Country
- Germany
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ascelia Pharma AB Business Overview & Revenue Model
Company Description
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trial...
Ascelia Pharma AB Peers Comparison
Overall Rating
SE:CANTA61Neutral
SE:ONCO44Neutral
SE:BINV43Neutral
SE:IMMU39Underperform
SE:ONCOZ39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | SEK 391.34M | 2.04 | 63.09% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | SEK 763.50M | -2.81 | ― | ― | 65.37% | 43.28% | |
| 43Neutral | SEK 191.82M | -0.39 | -128.54% | ― | -83.67% | -50.29% | |
| 39Underperform | SEK 276.26M | -2.43 | -19.14% | ― | ― | 13.06% | |
| 39Underperform | SEK 89.57M | -1.38 | -970.69% | ― | 115.26% | -230.43% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:7ZA | Ascelia Pharma AB | 0.04 | -0.22 | -83.14% | |
| SE:BINV | BioInvent International AB | 2.92 | -26.98 | -90.25% | |
| SE:ONCO | Oncopeptides AB | 1.77 | -3.13 | -63.86% | |
| SE:ONCOZ | OncoZenge AB | 3.25 | -1.68 | -34.07% | |
| SE:IMMU | Immunicum AB | 4.36 | -1.30 | -23.06% | |
| SE:CANTA | Cantargia AB | 1.39 | -2.06 | -59.77% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
